These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11488373)

  • 21. Adjunctive clonazepam in the treatment of chronic schizophrenia.
    Herrera JM; Alvarez WA; Freinhar JP; Lawson WB; Sramek JJ
    Int J Psychosom; 1991; 38(1-4):17-20. PubMed ID: 1685726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risperidone and paroxetine given singly and in combination for bipolar depression.
    Shelton RC; Stahl SM
    J Clin Psychiatry; 2004 Dec; 65(12):1715-9. PubMed ID: 15641878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study.
    Salokangas RK; Saarijärvi S; Taiminen T; Kallioniemi H; Lehto H; Niemi H; Tuominen J; Ahola V; Syvälahti E
    Acta Psychiatr Scand; 1996 Sep; 94(3):175-80. PubMed ID: 8891083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology.
    Agid O; Lerer B
    J Clin Psychiatry; 1999 Jan; 60(1):55-6. PubMed ID: 10074882
    [No Abstract]   [Full Text] [Related]  

  • 25. [Obsessive-compulsive disorder and schizophrenia].
    Denda K
    Ryoikibetsu Shokogun Shirizu; 2003; (38):459-63. PubMed ID: 12877026
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effect of neuroleptics on depressive symptoms].
    Tabeze JP
    Encephale; 1998 Jul; 24 Spec No 1():38-41. PubMed ID: 9809254
    [No Abstract]   [Full Text] [Related]  

  • 27. May selective serotonin reuptake inhibitors (SSRIs) provide some benefit for the treatment of schizophrenia?
    Buoli M; Serati M; Ciappolino V; Altamura AC
    Expert Opin Pharmacother; 2016 Jul; 17(10):1375-85. PubMed ID: 27148641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
    Weihs KL; Settle EC; Batey SR; Houser TL; Donahue RM; Ascher JA
    J Clin Psychiatry; 2000 Mar; 61(3):196-202. PubMed ID: 10817105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.
    Bhowmick S; Hazra A; Ghosh M
    Aust N Z J Psychiatry; 2010 Mar; 44(3):237-42. PubMed ID: 20050717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.
    Ostroff RB; Nelson JC
    J Clin Psychiatry; 1999 Apr; 60(4):256-9. PubMed ID: 10221288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients.
    Ertugrul A; Anil Yagcioglu AE; Eni N; Yazici KM
    Psychiatry Clin Neurosci; 2005 Apr; 59(2):219-22. PubMed ID: 15823172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients.
    Goff DC; Brotman AW; Waites M; McCormick S
    Am J Psychiatry; 1990 Apr; 147(4):492-4. PubMed ID: 1969245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.
    Pollack MH; Zaninelli R; Goddard A; McCafferty JP; Bellew KM; Burnham DB; Iyengar MK
    J Clin Psychiatry; 2001 May; 62(5):350-7. PubMed ID: 11411817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study.
    Amodeo L; Castelli L; Leombruni P; Cipriani D; Biancofiore A; Torta R
    Support Care Cancer; 2012 Feb; 20(2):375-84. PubMed ID: 21404089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. L-deprenyl in treating negative symptoms of schizophrenia.
    Perenyi A; Goswami U; Frecska E; Arató M; Bela A
    Psychiatry Res; 1992 May; 42(2):189-91. PubMed ID: 1352903
    [No Abstract]   [Full Text] [Related]  

  • 37. Lower-dose therapy with traditional neuroleptics in chronically hospitalized schizophrenic patients.
    Smith RC
    Arch Gen Psychiatry; 1994 May; 51(5):427-9. PubMed ID: 7910013
    [No Abstract]   [Full Text] [Related]  

  • 38. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics.
    Reznik I; Sirota P
    J Clin Psychopharmacol; 2000 Aug; 20(4):410-6. PubMed ID: 10917401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The treatment of negative symptoms: pharmacological and methodological issues.
    Carpenter WT
    Br J Psychiatry Suppl; 1996 May; (29):17-22. PubMed ID: 8733819
    [No Abstract]   [Full Text] [Related]  

  • 40. Occupancy of serotonin transporters in the amygdala by paroxetine in association with attenuation of left amygdala activation by negative faces in major depressive disorder.
    Ruhé HG; Koster M; Booij J; van Herk M; Veltman DJ; Schene AH
    Psychiatry Res; 2014 Feb; 221(2):155-61. PubMed ID: 24406081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.